Karyopharm Therapeutics (NASDAQ:KPTI) Announces Quarterly Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) posted its quarterly earnings results on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02, Zacks reports. The company had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.

Karyopharm Therapeutics Trading Down 4.8 %

Shares of NASDAQ:KPTI opened at $0.60 on Thursday. The stock has a market capitalization of $75.71 million, a PE ratio of -0.53 and a beta of 0.06. Karyopharm Therapeutics has a 1 year low of $0.53 and a 1 year high of $1.70. The firm has a fifty day moving average price of $0.67 and a 200 day moving average price of $0.76.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on KPTI shares. Piper Sandler increased their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Monday, February 10th. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).